Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines

Seminars in Cancer Biology

Volumn 14, Issue 3, 2004, Pages 161-169

  Vicari, Alain P ^a   Treilleux, Isabelle ^b   Lebecque, Serge ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Chemokine; Dendritic cell; Immunity; Tolerance; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CARCINOGENESIS; CELL MIGRATION; DENDRITIC CELL; HUMAN; MIGRATION; NONHUMAN; REVIEW;

EID: 2342575714     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.10.002     Document Type: Article

References (101)

1. Burnet F.M. The concept of immunological surveillance. Prog. Exp. Tumour Res. 13:1970;1-27
2. Saleh F.H., Crotty K.A., Hersey P., Menzies S.W., Rahman W. Autonomous histopathological regression of primary tumors associated with specific immune responses to cancer antigens. J. Pathol. 200:2003;383-395
3. Boon T., Old L.J. Cancer tumour antigens. Curr. Opin. Immunol. 9:1997;681-683
4. Albert M.L., Darnell J.C., Bender A., Francisco L.M., Bhardwaj N., Darnell R.B. Tumour-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4:1998;1321-1324
5. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183-1187
6. Schuler G., Schuler-Thurner B., Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:2003;138-147
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252
8. de Saint-Vis B., Vincent J., Vandenabeele S., Vanbervliet B., Pin J.J., Ait-Yahia S., et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 9(3):1998;325-336
9. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:2002;151-161
10. Caux C., Ait-Yahia S., Chemin K., de Bouteiller O., Dieu-Nosjean M.C., Homey B., et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer. Semin. Immunopathol. 22:2000;345-369
11. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3:2002;1135-1141
12. Huang F.P., Platt N., Wykes M., Major J.R., Powell T.J., Jenkins C.D., et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J. Exp. Med. 191:2000;435-444
13. Geissmann F., Dieu-Nosjean M.C., Dezutter C., Valladeau J., Kayal S., Leborgne M., et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J. Exp. Med. 196:2002;417-430
14. Yoshino M., Yamazaki H., Nakano H., Kakiuchi T., Ryoke K., Kunisada T., et al. Distinct antigen trafficking from skin in the steady and active states. Int. Immunol. 15:2003;773-779
15. Verbovetski I., Bychkov H., Trahtemberg U., Shapira I., Hareuveni M., Ben-Tal O., et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J. Exp. Med. 196:2002;1555-1561
16. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:2001;233-238
17. Vicari A.P., Caux C., Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12:2002;33-42
18. Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M., Liu Y., et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 12:2000;71-81
19. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7:2001;1339-1346
20. Vermi W., Bonecchi R., Facchetti F., Bianchi D., Sozzani S., Festa S., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200:2003;255-268
21. Salio M., Cella M., Vermi W., Facchetti F., Palmowski M.J., Smith C.L., et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Err. J. Immunol. 33:2003;1052-1062
22. Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., et al. In breast carcinoma tissue, immature dendritic cells reside within the tumour, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190:1999;1417-1426
23. Suzuki A., Masuda A., Nagata H., Kameoka S., Kikawada Y., Yamakawa M., et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J. Pathol. 196(1):2002;37-43
24. Scarpino S., Stoppacciaro A., Ballerini F., Marchesi M., Prat M., Stella M.C., et al. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumour cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 156:2000;831-837
25. Lewko B., Zoltowska A., Stepinski J., Roszkiewicz A., Moszkowska G. Dendritic and cancer cells in the breast tumors-an immunohistochemical study: short communication. Med. Sci. Monit. 6(5):2000;892-895
26. Lespagnard L., Gancberg D., Rouas G., Leclercq G., de Saint-Aubain Somerhausen N., Di Leo A., et al. Tumour-infiltrating dendritic cells in neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int. J. Cancer. 84:1999;309-314
27. Schwaab T., Weiss J.E., Schned A.R., Barth R.J. Jr. Dendritic cell infiltration in colon cancer. J. Immunother. 24(2):2001;130-137
28. Tang K.F., Tan S.Y., Chan S.H., Chong S.M., Loh K.S., Tan L.K., et al. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumour infiltration by T lymphocytes and macrophages. Hum. Pathol. 32:2001;42-49
29. Negus R.P., Stamp G.W., Hadley J., Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150:1997;1723-1734
30. Dieu M.C., Vanbervliet B., Vicari A.P., Bridon J.M., Oldham E., Ait-Yahia S., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:1998;373-386
31. Kleeff J., Kusama T., Rossi D.L., Ishiwata T., Maruyama H., Friess H., et al. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer. 81:1999;650-657
32. Elgert K.D., Alleva D.G., Mullins D.W. Tumour-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64:1998;275-290
33. Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumour-associated macrophages. Immunol. Today. 13:1992;265-270
34. Goede V., Brogelli L., Ziche M., Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer. 82:1999;765-770
35. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J.Y. The host-tumour immune conflict: from immunosuppression to resistance and destruction. Immunol. Today. 18:1997;493-497
36. Bottazzi B., Colotta F., Sica A., Nobili N., Mantovani A. A chemoattractant expressed in human sarcoma cells (tumour-derived chemotactic factor, TDCF) is identical to monocyte chemoattractant protein-1/monocyte chemotactic and activating factor (MCP-1/MCAF). Int. J. Cancer. 45:1990;795-797
37. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science. 220:1983;210-212
38. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6:2000;3282-3289
39. Yamashiro S., Takeya M., Nishi T., Kuratsu J., Yoshimura T., Ushio Y., et al. Tumour-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am. J. Pathol. 145:1994;856-867
40. Amann B., Perabo F.G., Wirger A., Hugenschmidt H., Schultze-Seemann W. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br. J. Urol. 82:1998;118-121
41. Valkovic T., Lucin K., Krstulja M., Dobi-Babic R., Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol. Res. Pract. 194:1998;335-340
42. Van Damme J., Proost P., Lenaerts J.P., Opdenakker G. Structural and functional identification of two human, tumour-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J. Exp. Med. 176:1992;59-65
43. Rollins B.J., Sunday M.E. Suppression of tumour formation in vivo by expression of the JE gene in malignant cells. Mol. Cell Biol. 11:1991;3125-3131
44. Huang S., Singh R.K., Xie K., Gutman M., Berry K.K., Bucana C.D., et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol. Immunother. 39:1994;231-238
45. Hoshino Y., Hatake K., Kasahara T., Takahashi Y., Ikeda M., Tomizuka H., et al. Monocyte chemoattractant protein-1 stimulates tumour necrosis and recruitment of macrophages into tumors in tumour-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow. Exp. Hematol. 23:1995;1035-1039
46. Nakashima E., Mukaida N., Kubota Y., Kuno K., Yasumoto K., Ichimura F., et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res. 12:1995;1598-1604
47. Bottazzi B., Walter S., Govoni D., Colotta F., Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148:1992;1280-1285
48. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha. J. Exp. Med. 179:1994;1109-1118
49. Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science. 282:1998;480-483
50. Randolph G.J., Inaba K., Robbiani D.F., Steinman R.M., Muller W.A. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 11:1999;753-761
51. Grage-Griebenow E., Flad H.D., Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J. Leukoc. Biol. 69:2001;11-20
52. + monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood. 95:1995;2910-2917
53. + monocytes. J. Exp. Med. 197:2003;1701-1707
54. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 19:2003;71-82
55. Randolph G.J., Sanchez-Schmitz G., Liebman R.M., Schakel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 19:2002;517-527
56. McKenna H.J. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8:2001;149-154
57. Zou G.M., Tam Y.K. Cytokines in the generation and maturation of dendritic cells: recent advances. Err. Cytokine Netw. 13:2002;186-199
58. Mohamadzadeh M., Berard F., Essert G., Chalouni C., Pulendran B., Davoust J., et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 194:2001;1013-1020
59. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294:2001;1540-1543
60. Dranoff G. GM-CSF-based cancer vaccines. Immunol. Rev. 188:2002;147-154
61. Maliszewski C. Dendritic cells in models of tumour immunity. Role of Flt3 ligand. Pathol. Biol. 49:2001;481-483
62. Randolph G.J. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin. Immunol. 13:2001;267-274
63. Triozzi P.L., Khurram R., Aldrich W.A., Walker M.J., Kim J.A., Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 89:2000;2646-2654
64. Hirao M., Onai N., Hiroishi K., Watkins S.C., Matsushima K., Robbins P.D., et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumour cells: critical role in migration from the tumour site to draining lymph nodes. Cancer Res. 60:2000;2209-2217
65. Remmel E., Terracciano L., Noppen C., Zajac P., Heberer M., Spagnoli G.C., et al. Modulation of dendritic cell phenotype and mobility by tumour cells in vitro. Hum. Immunol. 62:2001;39-49
66. Homey B., Muller A., Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2:2002;175-184
67. Fioretti F., Fradelizi D., Stoppacciaro A., Ramponi S., Ruco L., Minty A., et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumour. J. Immunol. 161:1998;342-346
68. Giovarelli M., Cappello P., Forni G., Salcedo T., Moore P.A., LeFleur D.W., et al. Tumour rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164:2000;3200-3206
69. Vicari A.P., Ait-Yahia S., Chemin K., Mueller A., Zlotnik A., Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165:2000;1992-2000
70. Fushimi T., Kojima A., Moore M.A., Crystal R.G. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumour growth. J. Clin. Invest. 105:2000;1383-1393
71. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61:2001;2062-2070
72. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164:2000;4558-4563
73. Nomura T., Hasegawa H., Kohno M., Sasaki M., Fujita S. Enhancement of anti-tumour immunity by tumour cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int. J. Cancer. 91:2001;597-606
74. Sharma S., Stolina M., Zhu L., Lin Y., Batra R., Huang M., et al. Secondary lymphoid organ chemokine reduces pulmonary tumour burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 61:2001;6406-6412
75. Sharma S., Yang S.C., Hillinger S., Zhu L.X., Huang M., Batra R.K., et al. SLC/CCL21-mediated anti-tumour responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer. 2:2003;22
76. Braun S.E., Chen K., Foster R.G., Kim C.H., Hromas R., Kaplan M.H., et al. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumour rejection of murine breast cancer cells through NK cells. J. Immunol. 164:2000;4025-4031
77. Sallusto F., Mackay C.R., Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:2000;593-620
78. Kim C.H., Pelus L.M., Appelbaum E., Johanson K., Anzai N., Broxmeyer H.E. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. Cell Immunol. 193:1999;226-235
79. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1999;1124-1125
80. Gilliet M., Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195:2002;695-704
81. Krug A., Veeraswamy R., Pekosz A., Kanagawa O., Unanue E.R., Colonna M., et al. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J. Exp. Med. 197:2003;899-906
82. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 284:1999;1835-1837
83. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST1684. J. Clin. Oncol. 14:1996;7-17
84. Kadowaki N., Antonenko S., Liu Y.J. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166:2001;2291-2295
85. Ito T., Amakawa R., Kaisho T., Hemmi H., Tajima K., Uehira K., et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195:2002;1507-1512
86. Asselin-Paturel C., Boonstra A., Dalod M., Durand I., Yessaad N., Dezutter-Dambuyant C., et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2:2001;1144-1150
87. Brocker T., Riedinger M., Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J. Exp. Med. 185:1997;541-550
88. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity. 19:2003;5-8
89. Probst H.C., Lagnel J., Kollias G., van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity. 18:2003;713-720
90. Chiodoni C., Paglia P., Stoppacciaro A., Rodolfo M., Parenza M., Colombo M.P. Dendritic cells infiltrating tumors cotransduced with granulocyte/ macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and presentendogenous tumour-associated antigens, and prime naive mice for a cytotoxic Tlymphocyte response. J. Exp. Med. 190:1999;125-133
91. Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., et al. Reversal of tumour-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196:2002;541-549
92. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:2003;562-567
93. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:2003;253-257
94. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:2001;4766-4772
95. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumour microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:2002;2756-2761
96. + T cells: a common basis between tumour immunity and autoimmunity. J. Immunol. 163:1999;5211-5218
97. + regulatory T cells: their common role in controlling autoimmunity, tumour immunity, and transplantation tolerance. Immunol. Rev. 182:2001;18-32
98. Geijtenbeek T.B., Torensma R., van Vliet S.J., van Duijnhoven G.C., Adema G.J., van Kooyk Y., Figdor C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell. 100(5):2000;575-585
99. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 185(6):1997;1101-1111
100. Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med. 194(12):2001;1823-1834
101. Horny H.P., Feller A.C., Horst H.A., Lennert K. Immunocytology of plasmacytoid T cells: marker analysis indicates a unique phenotype of this enigmatic cell. Hum. Pathol. 18(1):1987;28-32